MedTrace Logo

Home-Based tDCS Treatment Of Major Depressive Disorder

NCT06976697 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-03-23

No results posted yet for this study

Summary

The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DEVICE

Transcranial direct current stimulation

In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.

DEVICE

Sham transcranial direct current stimulation

Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.

Sponsors & Collaborators

  • Sooma Medical Inc

    lead INDUSTRY

Principal Investigators

  • Christopher Reist, M.D.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2026-10-10
Completion
2026-12-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06976697 on ClinicalTrials.gov